A Two-part Phase 1 Randomized, Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of GSK3862995B Following Single Ascending Doses in Healthy Participants and Repeat Doses in Participants With Chronic Obstructive Pulmonary Disease
The primary objective of the study is to investigate the safety and tolerability of ascending doses of GSK3862995B following single dose in healthy participants and repeat doses in participants with Chronic obstructive pulmonary disease (COPD).
⁃ Healthy participants (Part A)
• Participant must be 18 to 65 years of age inclusive.
• Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring
• Body weight within the range 50-110 kilogram (kg) (inclusive)
• Body mass index (BMI) within the range 19.5-32 kilogram per square meter (kg/m\^2)
• Male and/or female of non-childbearing potential
⁃ Participants with Chronic Obstructive Pulmonary Disorder (COPD) (Part B)
• Participant must be 40 to 75 years of age inclusive.
• Body weight within the range 50-110 kg (inclusive)
• BMI within the range 19.5-32 kg/m\^2
• Participant has a confirmed diagnosis of COPD for greater than (\>)12 months
• Participants must present with a measured post-salbutamol Forced expiratory volume in 1 second/Forced vital capacity (FEV1/FVC) ratio of less than (\<) 0.70 at screening to confirm the diagnosis of COPD and a measured post-salbutamol FEV1 greater than or equal to (\>=) 40% of predicted normal values.
• Participants must have a well-documented requirement for optimized standard of care background therapy that includes daily inhaled medication.
• A peripheral blood eosinophil count of \>=150 cells/microliter (mcL) at screening
• Former cigarette smokers with a history of cigarette smoking of \>=10 pack-years at screening current smokers (includes the use of any type of nicotine containing product), or non-smokers are permitted
• Male and/or female of non-childbearing potential.